U.S. Transportation Stock News

Tempus AI stock has rallied strongly in the past month, yet its valuation checks are pulling in different directions, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) pointing to upside while market multiples lean expensive. Tempus AI has returned 54.8% over the past month, which puts extra focus on whether recent optimism is already reflected in the share price. The surge in interest following positive cancer vaccine trial news and the planned US$1.5b Personalis...

Services activity in the United States is currently the strongest it has been in 20 months, which highlights how much of daily life is shifting toward digital and data driven experiences. That dependence on software and cloud infrastructure keeps artificial intelligence and ChatGPT linked tools in sharp focus for investors hunting for growth themes. This article walks through 3 AI stocks from the screener that help turn that theme into a practical watchlist. The three stocks below are just a...

LeMaitre Vascular (LMAT) has drawn investor attention after its share price declined about 17% over the past month and about 16% over the past 3 months, prompting fresh questions about valuation and fundamentals. See our latest analysis for LeMaitre Vascular. At a share price of US$81.86, LeMaitre Vascular has seen short term momentum fade, with the 30 day share price return down 17.15% and the 1 year total shareholder return down 17.58%, even though the 3 and 5 year total shareholder returns...

Earlier in fiscal 2026, RPM International reported a strong fourth-quarter, with adjusted earnings and net sales both topping estimates and rising from the prior year. Management also issued guidance for fiscal 2027 calling for mid-single-digit sales growth and higher adjusted EBITDA, signaling confidence across all segments. Next, we’ll examine how RPM’s upbeat fiscal 2027 sales and EBITDA outlook influences the existing investment narrative around pricing power and efficiency. The future...

Earlier this month, North America's Building Trades Unions, BlackRock, and the AI Infrastructure Partnership signed a Memorandum of Understanding to support US AI and energy infrastructure buildout, expand workforce training, and improve project execution at data centers and related facilities. This agreement is interesting because it directly links BlackRock’s AI and energy infrastructure ambitions with a structured pipeline of skilled labor and apprenticeship programs, potentially...

Everpure (NYSE:P) has been recognized as a Leader in the 2026 Gartner Magic Quadrant for Enterprise Storage Platforms. This is the second consecutive year Everpure has appeared in the Leader quadrant. The recognition highlights Gartner's assessment of Everpure's execution in enterprise storage and completeness of vision. Everpure is one of several companies tied to the build out of modern storage and AI infrastructure. It can be useful to compare this story with a wider group of stocks...

In August 2026, Teva Pharmaceuticals announced that the FDA accepted and granted Priority Review to its New Drug Application for ecopipam, a first-in-class D1 receptor antagonist for pediatric Tourette syndrome, supported by positive Phase 2b and Phase 3 data and backed by Orphan Drug designation. If approved, ecopipam could become the first new pediatric Tourette syndrome treatment in more than a decade and introduce a novel mechanism of action in this condition for the first time in over...

Pathward Financial stock has delivered a strong 73.9% return over the past three years, yet its current valuation checks still suggest the shares lean cheap rather than fully priced. Over the last three years, Pathward Financial has returned 73.9%, which puts more focus on whether the current share price still offers a margin of value support. The key driver for the valuation case is how consistently Pathward Financial can convert its business model into earnings and cash flow, while the...

BioCryst Pharmaceuticals (BCRX) has drawn fresh attention after recent trading left the stock around $9.55, with returns that differ sharply across timeframes. Investors are now weighing this performance against the company’s rare disease drug portfolio. See our latest analysis for BioCryst Pharmaceuticals. Over the past year, BioCryst Pharmaceuticals has seen a mixed picture, with the share price at $9.55 supported by a 27.33% year to date share price return, but a 5 year total shareholder...

Quanta Services stock has delivered a very large 5 year return, yet the latest valuation work suggests the current US$639.34 share price is trading at a premium to its intrinsic value estimate. Quanta Services has returned roughly 5.2x an initial investment over 5 years, which puts extra focus on whether the current price still offers a comfortable margin of safety. The business can benefit if investors continue to expect solid long term cash generation from its infrastructure projects...

Ardelyx recently cut its full-year 2026 IBSRELA revenue guidance to US$350–US$370 million, withdrew a long-term XPHOZAH sales target, filed a US$36 million shelf registration for an ESOP-related common stock offering, and announced the past resignation of Chief Commercial Officer Eric Foster effective August 28, 2026. Together, the lowered guidance, withdrawal of a key revenue goal, and leadership change underscore how payer hurdles are pressuring Ardelyx’s commercial execution and long-term...

With the Buffett Indicator hovering around 238% and Warren Buffett himself content to sit on a growing pile of cash and T bills, many investors are wondering whether more of their portfolio should also lean toward short duration assets. Elevated valuations and the war in Iran have sharpened interest in cash style exposure. This article unpacks that story and walks through 3 stocks exposed to this theme. The stocks covered below are just a starting sample of this short duration cash theme, and...

With the U.S. slapping 50% tariffs on selected Canadian imports and Canada firing back with dollar for dollar measures, cross border supply chains are under fresh pressure. That kind of shock can hurt some stocks and create room for others that are tied more closely to U.S. manufacturing and onshoring. This article walks through 3 stocks exposed to this news and how the shifting trade backdrop could matter for their stories. The stocks covered below are just a starting sample. The full screen...

Roblox stock has had a tough run over the past year, yet current valuation checks still suggest the shares are not a clear bargain even after that pullback. Roblox has declined 67.4% over the past year, which raises the question of whether recent weakness has been fully reflected in the current share price. Expectations for user and revenue growth can support the case for paying up for Roblox, while the ongoing investigation into alleged misrepresentations by certain officers and directors...

Virtus Investment Partners (VRTS) is back in focus after converting two Zevenbergen mutual funds into actively managed ETFs and announcing a higher quarterly dividend, developments that may influence how you think about the stock today. See our latest analysis for Virtus Investment Partners. Over the past year, Virtus Investment Partners has seen its share price show shorter term momentum, with a 90 day share price return of 16.34%, even as the 1 year total shareholder return declined 11.31%...

Lamb Weston Holdings stock has enjoyed a strong rebound this year, yet its recent history and valuation checks suggest investors may still be paying up for the shares. After a three year period where the stock declined 40.1%, the current pricing raises questions about how much of a recovery is already reflected in the market value. Over the past 3 years, Lamb Weston Holdings has delivered a 40.1% decline, which points to a challenging stretch for long term holders even with the more recent...

With Treasury yields hovering near multi year highs and rate cuts looking less certain, investors are weighing what higher borrowing costs and a stronger dollar could mean for long term portfolios. This is creating an opening for those who care about steady income and valuation discipline but also feel the recent pullback in equities might be overdone in places. This article walks through three dividend payers from our high quality screener that appear well aligned with the latest macro...

Vertex Pharmaceuticals (VRTX) lifted its full year 2026 revenue guidance after citing continued demand in cystic fibrosis treatments and broader uptake in sickle cell disease, beta thalassemia, and acute pain therapies. See our latest analysis for Vertex Pharmaceuticals. The guidance upgrade comes after a strong run in Vertex Pharmaceuticals stock, with a 30 day share price return of 15.97% and a 90 day share price return of 26.13%. The 1 year total shareholder return of 38.70% and 5 year...

Best Buy recently reported quarterly results for the period ended July 2026, with Wall Street having anticipated higher year-over-year earnings supported by increased revenues and the possibility of an earnings beat based on a positive Earnings ESP. This setup highlighted how even small differences between the Most Accurate Estimate and the broader consensus can meaningfully shift expectations around Best Buy’s near-term earnings momentum. Next, we’ll examine how the anticipated earnings...

Rare Element Resources (OTCPK:REEM.F) moved into focus after the company addressed online market research materials suggesting a possible new investment and an announcement as early as August 26, 2026. See our latest analysis for Rare Element Resources. The sharp 1 day share price decline of 28.45% and 7 day share price fall of 7.97% came after Rare Element Resources clarified that online speculation about a potential investment was unfounded. However, the 30 day share price return of 176.13%...

PHINIA (PHIN) shares are trading against a backdrop of leadership and segment changes after the company appointed Pedro Abreu as President of Power Systems and Daniel Griffin as President of Aftermarket Solutions. See our latest analysis for PHINIA. At a share price of US$72.75, PHINIA has had a 1 day share price return of 1.56%, while the 30 day share price return is down 8.77% and the 1 year total shareholder return is 26.52%. This suggests that longer term momentum has held up even as the...

HCA Healthcare recently reported a solid Q2 2026 performance with strong revenue and patient-volume growth, even as it trimmed its full-year outlook to reflect payer and service-mix pressures. Alongside plans to present at several upcoming healthcare conferences and continued investment in emergency care capacity, HCA is signaling an emphasis on operational efficiency and technology as it balances growth with reimbursement headwinds. Next, we will examine how HCA’s strong quarterly results...

Kimbell Royalty Partners (NYSE:KRP) closed a US$221.2 million acquisition, expanding its mineral and royalty interests in key US oil and gas basins. The transaction increases Kimbell's asset base and exposure to production cash flows tied to these properties. The deal represents a material development for investors focused on US energy royalty and mineral exposure. For readers interested in more ways to play resource linked cash flows, the next useful step is to review 28 best rare earth...

Texas Instruments (TXN) is drawing fresh attention after one valuation model lifted its fair value estimate from US$298.00 to US$324.45, giving investors an updated reference point for evaluating potential upside and downside. See our latest analysis for Texas Instruments. Despite recent strength in Q2 results and a higher fair value estimate, Texas Instruments’ share price has eased. The 30 day share price return is down 10.14% and the 90 day share price return is down 14.50%, while the 1...